Takeda’s Deleveraging Begins with Ethicon and Novartis Deals

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 5 (Table of Contents)

Published: 14 May-2019

DOI: 10.3833/pdr.v2019.i5.2424     ISSN: 1756-7874

Section: Mergers & Acquisitions



Takeda has agreed to divest two of its non-core assets in a bid to streamline its portfolio to focus on its four core business areas...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details